Image_7_A Five-Gene-Pair-Based Prognostic Signature for Predicting the Relapse Risk of Early Stage ER+ Breast Cancer.TIF
About 20–30% of early-stage breast cancer patients suffer relapses after surgery. To identify such high-risk patients, many signatures have been reported, but they lack robustness in data measured on different platforms. Here, we developed a signature which is robust across multiple profiling platforms, and identified reproducible omics features characterizing metastasis of estrogen receptor (ER)-positive breast cancer from the Gene Expression Omnibus database with the aid of the signature. Based on the stable within-sample relative expression orderings (REOs), we constructed a signature consisting of five gene pairs, named 5-GPS, whose REOs were significantly correlated with relapse-free survival using the univariate Cox regression model. Using 5-GPS, patients were classified into the low-risk and high-risk groups. Patients in the high-risk group have worse survival compared to those in the low-risk group using Kaplan-Meier curve analysis with the log-rank test. Applying 5-GPS to the RNA-sequencing data of stage I-IV breast cancer samples archived in The Cancer Genome Atlas (TCGA), we found that the proportion of the high-risk patients increases with the stage. The proposed REO-based signature shows potential in identifying early-stage ER+ breast cancer patients with high risk of relapse after surgery.
History
References
- https://doi.org//10.1111/j.2517-6161.1995.tb02031.x
- https://doi.org//10.1007/s10549-016-3764-5
- https://doi.org//10.1016/s1470-2045(07)70346-7
- https://doi.org//10.18632/oncotarget.6260
- https://doi.org//10.7150/ijbs.24548
- https://doi.org//10.18632/oncotarget.14257
- https://doi.org//10.18632/oncotarget.15754
- https://doi.org//10.18632/oncotarget.11996
- https://doi.org//10.1038/s41375-018-0351-2
- https://doi.org//10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
- https://doi.org//10.1093/biomet/69.3.553
- https://doi.org//10.1111/j.0006-341x.2000.00337.x
- https://doi.org//10.1002/cncr.25870
- https://doi.org//10.1200/jco.2006.10.3523
- https://doi.org//10.1038/nature08987
- https://doi.org//10.1093/biostatistics/4.2.249
- https://doi.org//10.1038/ng.3312
- https://doi.org//10.1158/0008-5472.can-19-3095
- https://doi.org//10.1158/1541-7786.mcr-16-0408
- https://doi.org//10.1093/bib/bbv064
- https://doi.org//10.1002/mc.2940090208
- https://doi.org//10.1038/nbt.2957
- https://doi.org//10.1093/jnci/djj052
- https://doi.org//10.1093/jnci/djx133
- https://doi.org//10.1186/1471-2407-12-225
- https://doi.org//10.1038/bjc.2014.92
- https://doi.org//10.1016/s1043-321x(06)80430-3
- https://doi.org//10.18632/oncotarget.11341
- https://doi.org//10.21873/anticanres.13994
Usage metrics
Read the peer-reviewed publication
Categories
- Gene and Molecular Therapy
- Biomarkers
- Genetics
- Genetically Modified Animals
- Developmental Genetics (incl. Sex Determination)
- Epigenetics (incl. Genome Methylation and Epigenomics)
- Gene Expression (incl. Microarray and other genome-wide approaches)
- Livestock Cloning
- Genome Structure and Regulation
- Genetic Engineering
- Genomics